Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shield Arming Itself With Axis For Cardio Diagnostics Market Campaign

This article was originally published in The Gray Sheet

Executive Summary

Shield Diagnostics Group PLC's proposed merger with Olso, Norway-based Axis Biochemicals ASA, is an attempt to combine the companies' cardiovascular disease diagnostics technology to be supplied to hospital labs with clinical chemistry or immunoassay analyzers, the firms said Jan. 18.

You may also be interested in...



Global Diagnostics In Brief

Computer-aided detection: Siemens Medical's Mammomat Novation digital mammography system will integrate iCAD's Second Look Digital software as part of a three-year, worldwide licensing and distribution agreement. In a July 8 release, iCAD notes that U.S. product release is slated for 2005, following FDA approval of Mammomat, already cleared internationally. Last month, iCAD announced integration of its film-based analysis tool, Second Look 500M, with Confirma's MRI CAD to aid breast cancer detection....CADstream: Kirkland, Wash.-based Confirma launches CADstream 3.1 next-gen breast MRI analysis device July 8, following 510(k) clearance the previous day. The system includes SureLoc technology, allowing "automatic CAD-analysis and reporting of lesion location and calculations at the point of procedure," Confirma states. Other features include enhanced remote viewing and automatic reading capability within a 2-D region of interest. On July 1, GE Healthcare said it would distribute CADstream software to its global MRI customers...

ECHA Deliberates On Final Microplastic Proposal As Beauty Industry’s Fate Hangs In Balance

A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel